Tags

Type your tag names separated by a space and hit enter

[Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists].
Nihon Rinsho. 1996 Feb; 54(2):551-8.NR

Abstract

Lung tissues are capable of forming a large amount of thromboxane (TX) A2. In addition to platelet aggregation and artery smooth muscle contraction, TXA2 induces potent contraction of the airway smooth muscles and airway hypersensitivity, suggesting that this arachidonate cyclooxygenase metabolite can contribute to a pathophysiological role for bronchial asthma as well as cardiovascular diseases. In this respect, many compounds competitively antagonizing TP (PGH2/TXA2) receptor, which is stimulated by not only TXA2 but also prostaglandin (PG) D2, PGF2 alpha, PGH2 and others, have been developed so far. Among these, several compounds have been proved or are being proved to be beneficial for treating of bronchial asthma in clinical. In this review, the efficacy of TP receptor blockers for bronchial asthma through the experimental results reported was discussed.

Authors+Show Affiliations

Department of Pharmacology, Kyoto Pharmaceutical University.

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

8838113

Citation

Kohno, S. "[Molecular Pharmacology and Application to the Bronchial Asthma of Thromboxane A2 Antagonists]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 54, no. 2, 1996, pp. 551-8.
Kohno S. [Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists]. Nippon Rinsho. 1996;54(2):551-8.
Kohno, S. (1996). [Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 54(2), 551-8.
Kohno S. [Molecular Pharmacology and Application to the Bronchial Asthma of Thromboxane A2 Antagonists]. Nippon Rinsho. 1996;54(2):551-8. PubMed PMID: 8838113.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Molecular pharmacology and application to the bronchial asthma of thromboxane A2 antagonists]. A1 - Kohno,S, PY - 1996/2/1/pubmed PY - 1996/2/1/medline PY - 1996/2/1/entrez SP - 551 EP - 8 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nippon Rinsho VL - 54 IS - 2 N2 - Lung tissues are capable of forming a large amount of thromboxane (TX) A2. In addition to platelet aggregation and artery smooth muscle contraction, TXA2 induces potent contraction of the airway smooth muscles and airway hypersensitivity, suggesting that this arachidonate cyclooxygenase metabolite can contribute to a pathophysiological role for bronchial asthma as well as cardiovascular diseases. In this respect, many compounds competitively antagonizing TP (PGH2/TXA2) receptor, which is stimulated by not only TXA2 but also prostaglandin (PG) D2, PGF2 alpha, PGH2 and others, have been developed so far. Among these, several compounds have been proved or are being proved to be beneficial for treating of bronchial asthma in clinical. In this review, the efficacy of TP receptor blockers for bronchial asthma through the experimental results reported was discussed. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/8838113/[Molecular_pharmacology_and_application_to_the_bronchial_asthma_of_thromboxane_A2_antagonists]_ L2 - http://www.diseaseinfosearch.org/result/633 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.